Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial.

Cox MC, Castiello L, Mattei M, Santodonato L, D'Agostino G, Muraro E, Martorelli D, Lapenta C, Di Napoli A, Di Landro F, Cangemi M, Pavan A, Castaldo P, Hohaus S, Donati S, Montefiore E, Berdini C, Carlei D, Monque DM, Ruco L, Prosperi D, Tafuri A, Spadaro F, Sestili P, Spada M, Dolcetti R, Santini SM, Rozera C, Aricò E, Capone I, Belardelli F.

Clin Cancer Res. 2019 Sep 1;25(17):5231-5241. doi: 10.1158/1078-0432.CCR-19-0709. Epub 2019 Jun 6.

PMID:
31171545
2.

Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy.

Montico B, Lapenta C, Ravo M, Martorelli D, Muraro E, Zeng B, Comaro E, Spada M, Donati S, Santini SM, Tarallo R, Giurato G, Rizzo F, Weisz A, Belardelli F, Dolcetti R, Dal Col J.

Oncoimmunology. 2017 Jul 31;6(11):e1356964. doi: 10.1080/2162402X.2017.1356964. eCollection 2017.

3.

Breast cancer screening in patients with cancers other than breast.

Leopold RB, Thomas AW, Concannon KF, Correll AD, LaPenta CM, Maurer SM, Sprague BL, Herschorn SD, Verschraegen CF.

Breast Cancer Res Treat. 2017 Jun;163(2):343-348. doi: 10.1007/s10549-017-4179-7. Epub 2017 Mar 6.

4.

NK Cell Activation in the Antitumor Response Induced by IFN-α Dendritic Cells Loaded with Apoptotic Cells from Follicular Lymphoma Patients.

Lapenta C, Donati S, Spadaro F, Castaldo P, Belardelli F, Cox MC, Santini SM.

J Immunol. 2016 Aug 1;197(3):795-806. doi: 10.4049/jimmunol.1600262. Epub 2016 Jun 29.

5.

Epstein-Barr virus infection induces miR-21 in terminally differentiated malignant B cells.

Anastasiadou E, Garg N, Bigi R, Yadav S, Campese AF, Lapenta C, Spada M, Cuomo L, Botta A, Belardelli F, Frati L, Ferretti E, Faggioni A, Trivedi P.

Int J Cancer. 2015 Sep 15;137(6):1491-7. doi: 10.1002/ijc.29489. Epub 2015 Mar 4.

6.

IFN-α enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing.

Spadaro F, Lapenta C, Donati S, Abalsamo L, Barnaba V, Belardelli F, Santini SM, Ferrantini M.

Blood. 2012 Feb 9;119(6):1407-17. doi: 10.1182/blood-2011-06-363564. Epub 2011 Dec 19.

7.

Interferon-α-conditioned human monocytes combine a Th1-orienting attitude with the induction of autologous Th17 responses: role of IL-23 and IL-12.

Santini SM, Lapenta C, Donati S, Spadaro F, Belardelli F, Ferrantini M.

PLoS One. 2011 Feb 28;6(2):e17364. doi: 10.1371/journal.pone.0017364.

8.

Strong CD8+ T cell antigenicity and immunogenicity of large foreign proteins incorporated in HIV-1 VLPs able to induce a Nef-dependent activation/maturation of dendritic cells.

Sistigu A, Bracci L, Valentini M, Proietti E, Bona R, Negri DR, Ciccaglione AR, Tritarelli E, Nisini R, Equestre M, Costantino A, Marcantonio C, Santini SM, Lapenta C, Donati S, Tataseo P, Miceli M, Cara A, Federico M.

Vaccine. 2011 Apr 18;29(18):3465-75. doi: 10.1016/j.vaccine.2011.02.059. Epub 2011 Mar 5.

PMID:
21382480
9.

Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein.

Di Bonito P, Grasso F, Mochi S, Petrone L, Fanales-Belasio E, Mei A, Cesolini A, Laconi G, Conrad H, Bernhard H, Dembek CJ, Cosma A, Santini SM, Lapenta C, Donati S, Muratori C, Giorgi C, Federico M.

Virology. 2009 Dec 5;395(1):45-55. doi: 10.1016/j.virol.2009.09.012. Epub 2009 Oct 2.

10.

In vitro and in vivo efficacy of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on human melanoma.

Pellizzari Tregno F, Sau A, Pezzola S, Geroni C, Lapenta C, Spada M, Filomeni G, Bonanno E, Federici G, Caccuri AM.

Eur J Cancer. 2009 Sep;45(14):2606-17. doi: 10.1016/j.ejca.2009.06.033. Epub 2009 Aug 6.

PMID:
19665369
11.

Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin.

Nicoletti F, Lapenta C, Donati S, Spada M, Ranazzi A, Cacopardo B, Mangano K, Belardelli F, Perno C, Aquaro S.

Clin Exp Immunol. 2009 Jan;155(1):28-34. doi: 10.1111/j.1365-2249.2008.03780.x. Erratum in: Clin Exp Immunol. 2009 Apr;156(1):183. Lamenta, C [corrected to Lapenta, C].

12.

IFN-alpha in the generation of dendritic cells for cancer immunotherapy.

Santini SM, Lapenta C, Santodonato L, D'Agostino G, Belardelli F, Ferrantini M.

Handb Exp Pharmacol. 2009;(188):295-317. doi: 10.1007/978-3-540-71029-5_14. Review.

PMID:
19031032
13.

IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens.

Lapenta C, Santini SM, Spada M, Donati S, Urbani F, Accapezzato D, Franceschini D, Andreotti M, Barnaba V, Belardelli F.

Eur J Immunol. 2006 Aug;36(8):2046-60.

14.

Differentiation of monocyte-derived dendritic cells is associated with upregulation and activation of Rac-1 small GTPase.

Giammarioli AM, Gambardella L, Quaranta MG, Lapenta C, Santini SM, Belardelli F, Viora M, Malorni W.

FEBS Lett. 2006 May 29;580(13):3335-9. Epub 2006 May 8.

15.
16.

Pertussis toxin B-oligomer inhibits HIV infection and replication in hu-PBL-SCID mice.

Lapenta C, Spada M, Santini SM, Racca S, Dorigatti F, Poli G, Belardelli F, Alfano M.

Int Immunol. 2005 Apr;17(4):469-75. Epub 2005 Mar 3.

PMID:
15746245
17.
18.

Anti-nerve growth factor Ab abrogates macrophage-mediated HIV-1 infection and depletion of CD4+ T lymphocytes in hu-SCID mice.

Garaci E, Aquaro S, Lapenta C, Amendola A, Spada M, Covaceuszach S, Perno CF, Belardelli F.

Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8927-32. Epub 2003 Jul 9.

19.

A new type I IFN-mediated pathway for the rapid differentiation of monocytes into highly active dendritic cells.

Santini SM, Di Pucchio T, Lapenta C, Parlato S, Logozzi M, Belardelli F.

Stem Cells. 2003;21(3):357-62.

20.

CD2+/CD14+ monocytes rapidly differentiate into CD83+ dendritic cells.

Di Pucchio T, Lapenta C, Santini SM, Logozzi M, Parlato S, Belardelli F.

Eur J Immunol. 2003 Feb;33(2):358-67.

21.

The natural alliance between type I interferon and dendritic cells and its role in linking innate and adaptive immunity.

Santini SM, Di Pucchio T, Lapenta C, Parlato S, Logozzi M, Belardelli F.

J Interferon Cytokine Res. 2002 Nov;22(11):1071-80. Review.

PMID:
12513906
22.

Vaginal transmission of HIV-1 in hu-SCID mice: a new model for the evaluation of vaginal microbicides.

Di Fabio S, Giannini G, Lapenta C, Spada M, Binelli A, Germinario E, Sestili P, Belardelli F, Proietti E, Vella S.

AIDS. 2001 Nov 23;15(17):2231-8.

PMID:
11698695
23.

Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities.

Parlato S, Santini SM, Lapenta C, Di Pucchio T, Logozzi M, Spada M, Giammarioli AM, Malorni W, Fais S, Belardelli F.

Blood. 2001 Nov 15;98(10):3022-9.

24.

Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice.

Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T, Belardelli F.

J Exp Med. 2000 May 15;191(10):1777-88.

25.

Primary HIV-1 infection of human CD4+ T cells passaged into SCID mice leads to selection of chronically infected cells through a massive fas-mediated autocrine suicide of uninfected cells.

Parlato S, Santini SM, Lapenta C, Spada M, Logozzi M, Rizza P, Proietti E, Belardelli F, Fais S.

Cell Death Differ. 2000 Jan;7(1):37-47.

26.

Type I interferon is a powerful inhibitor of in vivo HIV-1 infection and preserves human CD4(+) T cells from virus-induced depletion in SCID mice transplanted with human cells.

Lapenta C, Santini SM, Proietti E, Rizza P, Logozzi M, Spada M, Parlato S, Fais S, Pitha PM, Belardelli F.

Virology. 1999 Oct 10;263(1):78-88.

28.

Human intestinal lamina propria lymphocytes are naturally permissive to HIV-1 infection.

Lapenta C, Boirivant M, Marini M, Santini SM, Logozzi M, Viora M, Belardelli F, Fais S.

Eur J Immunol. 1999 Apr;29(4):1202-8.

30.

Treatment of severe combined immunodeficiency mice with anti-murine granulocyte monoclonal antibody improves human leukocyte xenotransplantation.

Santini SM, Spada M, Parlato S, Logozzi M, Lapenta C, Proietti E, Belardelli F, Fais S.

Transplantation. 1998 Feb 15;65(3):416-20.

PMID:
9484763
31.

U937-SCID mouse xenografts: a new model for acute in vivo HIV-1 infection suitable to test antiviral strategies.

Lapenta C, Fais S, Rizza P, Spada M, Logozzi MA, Parlato S, Santini SM, Pirillo M, Belardelli F, Proietti E.

Antiviral Res. 1997 Nov;36(2):81-90.

PMID:
9443664
32.

[HIV Antigens as complement fixing circulating immune complexes].

Filippini P, Guarino M, Lapenta C, Marrocco C, Panico L, Messina V, Piccinino F, Sagnelli E.

Infez Med. 1997 Jul;5(3):178-81. Italian.

33.

[Serum anti-HIV IgA in seropositive patients and in subjects at risk of HIV infection].

Filippini P, Guarino M, Lapenta C, Marrocco C, Scolastico C, Panico L, Piccinino F, Sagnelli E.

Infez Med. 1997 Jun;5(2):107-10. Italian.

PMID:
14966396
34.

T-cell dysfunctions in hu-PBL-SCID mice infected with human immunodeficiency virus (HIV) shortly after reconstitution: in vivo effects of HIV on highly activated human immune cells.

Rizza P, Santini SM, Logozzi MA, Lapenta C, Sestili P, Gherardi G, Lande R, Spada M, Parlato S, Belardelli F, Fais S.

J Virol. 1996 Nov;70(11):7958-64.

35.

Application of group process model to performance appraisal development in a CQI environment.

LaPenta C, Jacobs GM.

Health Care Manage Rev. 1996 Fall;21(4):45-60.

PMID:
8922964
36.

Supplemental Content

Loading ...
Support Center